Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 393

Results For "ED"

10349 News Found

Replacing confusion with clarity: Global Cancer Care launches Mumbai ops to tackle detection delays
News | December 21, 2025

Replacing confusion with clarity: Global Cancer Care launches Mumbai ops to tackle detection delays

The initiative is focused on a problem that continues to plague cancer outcomes in India


Gut health crisis fuelling anxiety, early ageing & lifestyle diseases
Healthcare | December 21, 2025

Gut health crisis fuelling anxiety, early ageing & lifestyle diseases

The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing


Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease
Clinical Trials | December 21, 2025

Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease

SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers


Qihan Biotech launches first-in-human trial of off-the-shelf CAR-T therapy for refractory lupus
Clinical Trials | December 21, 2025

Qihan Biotech launches first-in-human trial of off-the-shelf CAR-T therapy for refractory lupus

The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation


EMA grants orphan drug status to Sanofi’s Efdoralprin Alfa for rare lung disease
Drug Approval | December 20, 2025

EMA grants orphan drug status to Sanofi’s Efdoralprin Alfa for rare lung disease

Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD


SandboxAQ, MapLight team up to target novel CNS therapy with AI-driven drug discovery
R&D | December 20, 2025

SandboxAQ, MapLight team up to target novel CNS therapy with AI-driven drug discovery

SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements


Alembic announces USFDA final approval for Travoprost Ophthalmic Solution USP, 0.004%
Drug Approval | December 20, 2025

Alembic announces USFDA final approval for Travoprost Ophthalmic Solution USP, 0.004%

Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension


Briefs:  APL Healthcare, Biocon, USFDA, Sun Pharma and Clean Fino-Chem
Drug Approval | December 20, 2025

Briefs: APL Healthcare, Biocon, USFDA, Sun Pharma and Clean Fino-Chem

USFDA determines Sun Pharma's Baska facility inspection classification as OAI


Cosette Pharmaceuticals launches first generic CIPRO HC with 180 Days market exclusivity
Drug Approval | December 20, 2025

Cosette Pharmaceuticals launches first generic CIPRO HC with 180 Days market exclusivity

The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,